Assistant Professor at University of California, San Diego, United States
Dr. Laura Elizabeth Bauman, a pediatric gastroenterologist, excels in both clinical and academic settings, making her a strong candidate for the Best Researcher Award. She completed her fellowship at Cincinnati Children’s Medical Center and has been recognized with several prestigious awards, including the Arnold W. Strauss Award and the Young Investigator Travel Award. Dr. Bauman’s leadership roles include co-directing the Fecal Microbial Transplant Program and spearheading quality improvement initiatives at Rady Children’s Pediatric IBD Center. As a peer reviewer for top journals and an active member of professional organizations, she contributes significantly to the advancement of pediatric gastroenterology. Her dedication to service is evident in her work with the Crohn’s and Colitis Foundation and her leadership in fostering inclusivity at Rady Children’s Hospital. While further expanding her grant funding and publication portfolio would strengthen her profile, Dr. Bauman’s commitment to research and patient care makes her an outstanding researcher.
Profile:
Education:
Dr. Laura Elizabeth Bauman has a robust academic background, beginning with her Bachelor of Arts in Human Biology from Stanford University in 2007. She went on to earn her Medical Doctorate from the Geisel School of Medicine at Dartmouth in 2012, where she conducted research under Dr. Kari Rosenkranz. Following medical school, Dr. Bauman completed her pediatric internship and residency at the University of Utah from 2012 to 2015, with mentorship from Drs. Mark Deneau and M. Kyle Jensen. She then pursued specialized training through a Pediatric Gastroenterology, Hepatology, and Nutrition Fellowship at Cincinnati Children’s Medical Center from 2015 to 2018, working with Dr. Lee A. Denson. This extensive education, paired with her research and clinical training in leading institutions, has equipped Dr. Bauman with the expertise needed to excel in pediatric gastroenterology, with a focus on inflammatory bowel diseases and clinical research.
Professional Experience:
Dr. Laura Elizabeth Bauman’s professional experience is marked by her dedication to pediatric gastroenterology and her leadership in both clinical and academic settings. Since completing her fellowship at Cincinnati Children’s Medical Center in 2018, she has played pivotal roles at Rady Children’s Hospital in San Diego, where she co-directs the Fecal Microbial Transplant Program and leads quality improvement initiatives for pediatric inflammatory bowel disease (IBD) patients. Dr. Bauman is a key member of the hospital’s Gastroenterology Fellowship Clinical Competency Committee and collaborates on interdisciplinary projects to enhance patient care. She also serves on national committees, such as the Crohn’s and Colitis Foundation’s Pediatric Affairs Committee, contributing to the development of educational resources and clinical guidelines. A peer reviewer for top gastroenterology journals, Dr. Bauman remains actively involved in research, mentorship, and patient care, solidifying her reputation as a leader in pediatric gastroenterology.
Research Skills:
Dr. Laura Elizabeth Bauman possesses advanced research skills honed through years of focused academic and clinical inquiry in pediatric gastroenterology. Her expertise lies in inflammatory bowel diseases (IBD), where she has led and contributed to numerous research projects aimed at improving clinical outcomes for pediatric patients. Dr. Bauman’s ability to design, implement, and oversee research is demonstrated by her leadership in quality improvement initiatives, such as developing standardized care protocols for acute severe colitis at Rady Children’s Hospital. She is skilled in interdisciplinary collaboration, as shown by her work on the Fecal Microbial Transplant Program and her involvement in the creation of the Inpatient Acute Severe Ulcerative Colitis order set. Additionally, Dr. Bauman is an experienced peer reviewer for leading journals and has been recognized with awards, including the Arnold W. Strauss Award. Her capacity to blend clinical practice with research makes her an asset to the field of pediatric gastroenterology.
Award and Recognition:
Dr. Laura Elizabeth Bauman has received numerous awards and recognitions that highlight her excellence in research, clinical practice, and education. Notably, she was awarded the prestigious Arnold W. Strauss Award, a competitive $10,000 grant aimed at advancing clinical fellows’ research, specifically for her work on refractory ulcerative colitis. She also earned the Young Investigator Travel Award from the Crohn’s and Colitis Congress, recognizing her contributions to cutting-edge research in pediatric gastroenterology. In 2013, she was honored with the Golden Apple Award from the University of Utah’s Department of Pediatrics for her exceptional teaching and mentorship of medical students. Additionally, Dr. Bauman was selected as a candidate for the National Center for Leadership in Academic Medicine in 2023, a professional development program for junior faculty at UC San Diego. These accolades reflect Dr. Bauman’s commitment to advancing her field and her outstanding capabilities as both a researcher and educator.
Conclusion:
Dr. Laura Elizabeth Bauman is an outstanding candidate for the Research for Best Researcher Award, with a deep commitment to advancing pediatric gastroenterology through research, leadership, and service. While areas such as increasing her publication profile and securing larger grants could further strengthen her candidacy, her current achievements in clinical research and professional development make her a highly competitive nominee for this award.
Publication Top Notes:
- Mould DR, Upton RN, Wojciechowski J.
Title: Dashboard systems: implementing pharmacometrics from bench to bedside
Journal: AAPS J
Year: 2014
Citations: 115 (as of September 2024)
- Eser A, Primas C, Reinisch S, et al.
Title: Prediction of individual serum infliximab concentrations in inflammatory bowel disease by a Bayesian dashboard system
Journal: J Clin Pharmacol
Year: 2018
Citations: 25 (as of September 2024)
- Hyams J, Walters TD, Crandall W, et al.
Title: Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn’s disease in children: REACH open-label extension
Journal: Curr Med Res Opin
Year: 2011
Citations: 229 (as of September 2024)
- Crombé V, Salleron J, Savoye G, et al.
Title: Long-term outcome of treatment with infliximab in pediatric-onset Crohn’s disease: a population-based study
Journal: Inflamm Bowel Dis
Year: 2011
Citations: 310 (as of September 2024)
- Wine E, Mack DR, Hyams J, et al.
Title: Interleukin-6 is associated with steroid resistance and reflects disease activity in severe pediatric ulcerative colitis
Journal: J Crohns Colitis
Year: 2013
Citations: 152 (as of September 2024)
- Hyams J, Crandall W, Kugathasan S, et al.; REACH Study Group
Title: Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children
Journal: Gastroenterology
Year: 2007
Citations: 945 (as of September 2024)
- Merras-Salmio L, Kolho KL.
Title: Clinical use of infliximab trough levels and antibodies to infliximab in pediatric patients with inflammatory bowel disease
Journal: J Pediatr Gastroenterol Nutr
Year: 2017
Citations: 62 (as of September 2024)
- Moore C, Corbett G, Moss AC.
Title: Systematic review and meta-analysis: serum infliximab levels during maintenance therapy and outcomes in inflammatory bowel disease
Journal: J Crohns Colitis
Year: 2016
Citations: 310 (as of September 2024)
- Frymoyer A, Hoekman DR, Piester TL, et al.
Title: Application of population pharmacokinetic modeling for individualized infliximab dosing strategies in Crohn disease
Journal: J Pediatr Gastroenterol Nutr
Year: 2017
Citations: 63 (as of September 2024)
- Vande Casteele N, Khanna R, Levesque BG, et al.
Title: The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn’s disease
Journal: Gut
Year: 2015
Citations: 725 (as of September 2024)